[1] |
Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis[J]. J Am Acad Dermatol, 2011,64(2):217⁃230. doi: 10.1016/j.jaad.2010.05.045.
|
[2] |
Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study[J]. Rheumatology (Oxford), 2006,45(5):614⁃620. doi: 10.1093/rheumatology/kei251.
|
[3] |
Leitenberger JJ, Cayce RL, Haley RW, et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases[J]. Arch Dermatol, 2009,145(5):545⁃550. doi: 10.1001/archdermatol.2009.79.
|
[4] |
Pequet MS, Holland KE, Zhao S, et al. Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients[J]. Br J Dermatol, 2014,170(4):895⁃900. doi: 10.1111/bjd. 12758.
|
[5] |
Kreuter A, Krieg T, Worm M, et al. German guidelines for the diagnosis and therapy of localized scleroderma[J]. J Dtsch Dermatol Ges, 2016,14(2):199⁃216. doi: 10.1111/ddg.12724.
|
[6] |
El⁃Kehdy J, Abbas O, Rubeiz N. A review of Parry⁃Romberg syndrome[J]. J Am Acad Dermatol, 2012,67(4):769⁃784. doi: 10.1016/j.jaad.2012.01.019.
|
[7] |
Careta MF, Leite Cda C, Cresta F, et al. Prospective study to evaluate the clinical and radiological outcome of patients with scleroderma of the face[J]. Autoimmun Rev, 2013,12(11):1064⁃1069. doi: 10.1016/j.autrev.2013.05.005.
|
[8] |
Berianu F, Cohen MD, Abril A, et al. Eosinophilic fasciitis: clinical characteristics and response to methotrexate[J]. Int J Rheum Dis, 2015,18(1):91⁃98. doi: 10.1111/1756⁃185X.12499.
|
[9] |
Schanz S, Fierlbeck G, Ulmer A, et al. Localized scleroderma: MR findings and clinical features[J]. Radiology, 2011,260(3):817⁃824. doi: 10.1148/radiol.11102136.
|
[10] |
Schanz S, Henes J, Ulmer A, et al. Response evaluation of musculoskeletal involvement in patients with deep morphea treated with methotrexate and prednisolone: a combined MRI and clinical approach[J]. AJR Am J Roentgenol, 2013,200(4):W376⁃W382. doi: 10.2214/AJR.12.9335.
|
[11] |
李明, 孙建方. 皮肤科结缔组织病诊治[M]. 北京: 北京大学医学出版社, 2017:295⁃297.
|
[12] |
Lebeaux D, Francès C, Barete S, et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients[J]. Rheumatology (Oxford), 2012,51(3):557⁃561. doi: 10.1093/rheumatology/ker366.
|
[13] |
Wright NA, Mazori DR, Patel M, et al. Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers[J]. JAMA Dermatol, 2016,152(1):97⁃99. doi: 10.1001/jamadermatol.2015.3648.
|
[14] |
Itin PH, Schiller P. Double⁃lined frontoparietal scleroderma en coup de sabre[J]. Dermatology, 1999,199(2):185⁃186. doi: 10. 1159/000018236.
|
[15] |
Christen⁃Zaech S, Hakim MD, Afsar FS, et al. Pediatric morphea (localized scleroderma): review of 136 patients[J]. J Am Acad Dermatol, 2008,59(3):385⁃396. doi: 10.1016/j.jaad.2008.05.005.
|
[16] |
Arkachaisri T, Vilaiyuk S, Li S, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures[J]. J Rheumatol, 2009,36(12):2819⁃2829. doi: 10.3899/jrheum.081284.
|
[17] |
Arkachaisri T, Vilaiyuk S, Torok KS, et al. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof⁃of⁃concept study[J]. Rheumatology (Oxford), 2010,49(2):373⁃381. doi: 10.1093/rheumatology/kep361.
|
[18] |
Torok KS, Kurzinski K, Kelsey C, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T⁃helper cell⁃associated cytokine profiles[J]. Semin Arthritis Rheum, 2015,45(3):284⁃293. doi: 10.1016/j.semarthrit.2015.06. 006.
|
[19] |
Mertens JS, Seyger M, Thurlings RM, et al. Morphea and eosinophilic fasciitis: an update[J]. Am J Clin Dermatol, 2017,18(4):491⁃512. doi: 10.1007/s40257⁃017⁃0269⁃x.
|
[20] |
Dańczak⁃Pazdrowska A, Kowalczyk M, Szramka⁃Pawlak B, et al. Interleukin⁃17A and interleukin⁃23 in morphea[J]. Arch Med Sci, 2012,8(6):1089⁃1095. doi: 10.5114/aoms.2012.32421.
|
[21] |
Arkachaisri T, Fertig N, Pino S, et al. Serum autoantibodies and their clinical associations in patients with childhood⁃ and adult⁃onset linear scleroderma. A single⁃center study[J]. J Rheumatol, 2008,35(12):2439⁃2444. doi: 10.3899/jrheum.080098.
|
[22] |
Yamane K, Ihn H, Kubo M, et al. Anti⁃U1RNP antibodies in patients with localized scieroderma[J]. Arch Dermatol Res, 2001,293(9):455⁃459. doi: 10.1007/s004030100254.
|
[23] |
Yimane K, Ihn H, Kubo M, et al. Anti⁃U3 snRNP antibodies in localised scleroderma[J]. Ann Rheum Dis, 2001,60(12):1157⁃1158. doi: 10.1136/ard.60.12.1157.
|
[24] |
Dupont S, Catala M, Hasboun D, et al. Progressive facial hemiatrophy and epilepsy: a common underlying dysgenetic mechanism[J]. Neurology, 1997,48(4):1013⁃1018. doi: 10.1212/ wnl.48.4. 1013.
|
[25] |
El⁃Kehdy J, Abbas O, Rubeiz N. A review of Parry⁃Romberg syndrome[J]. J Am Acad Dermatol, 2012,67(4):769⁃784. doi: 10.1016/j.jaad.2012.01.019.
|
[26] |
Asher SW, Berg BO. Progressive hemifacial atrophy: report of three cases, including one observed over 43 years, and computed tomographic findings[J]. Arch Neurol, 1982,39(1):44⁃46. doi: 10.1001/archneur.1982.00510130046011.
|
[27] |
Careta MF, Leite Cda C, Cresta F, et al. Prospective study to evaluate the clinical and radiological outcome of patients with scleroderma of the face[J]. Autoimmun Rev, 2013,12(11):1064⁃1069. doi: 10.1016/j.autrev.2013.05.005.
|
[28] |
Moko SB, Mistry Y, Blandin de Chalain TM. Parry⁃Romberg syndrome: intracranial MRI appearances[J]. J Craniomaxillofac Surg, 2003,31(5):321⁃324. doi: 10.1016/s1010⁃5182(03)00028⁃3.
|
[29] |
Terstegge K, Kunath B, Felber S, et al. MR of brain involvement in progressive facial hemiatrophy (Romberg disease): reconsideration of a syndrome[J]. AJNR Am J Neuroradiol, 1994,15(1):145⁃150.
|